The first antibiotic against tuberculosis that has been developed in Germany is now ready for clinical testing. BTZ043, as the newly developed drug substance is called, is also effective against multidrug-resistant pathogens which are increasingly challenging successful treatment worldwide. Scientists from the Ludwig-Maximilians-Universität (LMU) Munich and the Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (HKI) in Jena are leading this project. The German Center for Infection Research (DZIF) and the InfectControl 2020 consortium are funding a major part of the trials.
The problem of antibiotic resistance has increased sharply over the last decades. Today, we face the challenge of having to manage a growing number of multidrug-resistant pathogens against which only a few antibiotics have remained effective.
In the case of tuberculosis, the situation is particularly difficult as the treatment regimen still includes several antibiotics which need to be taken simultaneously. Additionally, mycobacteria, which cause tuberculosis, have many mechanisms with which they protect themselves against specific effects of different antibiotics. Consequently, several new agents, ideally with different modes of action, are urgently needed to develop new treatment forms.
New site on mycobacteria targeted
BTZ043 is the first member of a newly discovered class of antibiotics and chemically belongs to the benzothiazinones. “The agent irreversibly binds to an enzyme that is needed for bacterial cell wall synthesis,” explains Dr Florian Kloß, Head of the Transfer Group Antiinfectives of InfectControl 2020 at the HKI.
“As the enzyme can then no longer function, holes develop in the mycobacterial cell walls and the cell contents drain out,” adds DZIF scientist Prof Michael Hoelscher, Director of the Department of Infectious Diseases and Tropical Medicine at the LMU Munich (also see image). “The agent targets tuberculosis bacteria highly selectively and consequently does not affect other bacteria.”
Clinical trial tests tolerance
Recruitment of the first trial subjects for clinical testing of BTZ043 can now be initiated, following the approval of the Federal Institute for Drugs and Medical Devices (BfArM) and the Bavarian Chamber of Physicians’ Ethics Committee.
Led by Prof Hoelscher, up to 40 volunteers will receive the antibiotic at the trial centre of the company Nuvisan in Neu-Ulm. Hoelscher explains the procedure, “We want to ensure that the drug is absorbed by the body and is well-tolerated. To this end, a very low single dose will be administered, and subsequently this dose will gradually be increased for the next trial volunteers.” The aim of the trial is to reach the dose which showed good efficacy in animal models. This dose is far below the highest dose that the animals still tolerated well.
United against infections
A team of scientists and businessmen is involved in the development of this new tuberculosis drug. The agent, BTZ043, was discovered at the HKI in Jena. Since 2014, the drug has been developed further at the DZIF and InfectControl 2020 and other sites in a collaboration project between the Medical Center of the LMU Munich and the HKI.
The HKI is responsible for precise investigations of absorption, distribution, metabolism and excretion as well as for developing analytical methods for detecting metabolites. As a funder, the LMU Munich’s Medical Center is responsible for preclinical and clinical development as well as for quality and safety of the drug. The substance will be produced at Hapila GmbH, a medium-size pharmaceutical company in Gera.
Financing the drug development costs of several million euros has been made possible though joint public and private funding. Particularly the two research alliances DZIF and InfectControl 2020 are involved in developing the active agent. They are being funded by the Federal Ministry of Education and Research.
Prof Michael Hoelscher
Department of Infectious Diseases and Tropical Medicine at the Medical Center of LMU Munich
T +49 89 2180 17613
DZIF Press Office
Karola Neubert and Janna Schmidt
T +49 531 6181 1170/1154
Karola Neubert | idw - Informationsdienst Wissenschaft
New findings link estrogen and T cell immune response to autoimmune inflammation
01.06.2018 | University of Turku
Creating an automated high-throughput flow cytometry system
30.05.2018 | SLAS (Society for Laboratory Automation and Screening)
Light detection and control lies at the heart of many modern device applications, such as smartphone cameras. Using graphene as a light-sensitive material for...
Water molecules exist in two different forms with almost identical physical properties. For the first time, researchers have succeeded in separating the two forms to show that they can exhibit different chemical reactivities. These results were reported by researchers from the University of Basel and their colleagues in Hamburg in the scientific journal Nature Communications.
From a chemical perspective, water is a molecule in which a single oxygen atom is linked to two hydrogen atoms. It is less well known that water exists in two...
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
05.06.2018 | Event News
28.05.2018 | Event News
25.05.2018 | Event News
05.06.2018 | Earth Sciences
05.06.2018 | Life Sciences
05.06.2018 | Physics and Astronomy